GEN Exclusives

More »

GEN News Highlights

More »
Nov 15, 2012

Janssen Launches Clinical Trials Database

  • Janssen Research & Development today said it established a global cross-pharmaceutical Investigator Databank designed to save money, time, and effort spent carrying out industry-sponsored clinical trials.

    Merck and Eli Lilly will be the first two companies to join Janssen in the database initiative, which will house key information about investigators and clinical trial sites, such as infrastructure and Good Clinical Practice training records. The database will not include patient data.

    “The current clinical trial environment is inefficient, costly, and unsustainable. The Investigator Databank can help expedite the process,” Andreas Koester, M.D., Ph.D., Head, Clinical Trial Innovation/External Alliances, Janssen R&D, said in a statement.

    The Investigator Databank will serve as a foundation for the TransCelerate initiative, in which Janssen joined nine other companies to launch TransCelerate BioPharma, an effort to identify and overcome common drug development challenges with the goals of improving the quality of clinical studies and bringing new medicines to patients faster.

    TransCelerate member companies that wish to join the database automatically qualify for participation. The Investigator Databank is expected to be operational by the end of this year, and incorporated within TransCelerate by mid-2013.

    Hosting the Investigator Databank will be, which connects sponsors to investigators capable of conducting clinical trials while providing the researchers with access to opportunities for new studies.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »